{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:37:38Z","timestamp":1790797058296,"version":"4.1.0"},"reference-count":15,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,5,6]],"date-time":"2013-05-06T00:00:00Z","timestamp":1367798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2013,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>The frequency and the degree of recovery of anterior pituitary hormone deficits in patients with macroprolactinoma responsive to cabergoline are not clear. Our aim was to evaluate pituitary function in these patients with particular reference to an assessment of the possible restoration of pituitary deficits.<\/jats:p><\/jats:sec><jats:sec><jats:title>Subjects and Methods<\/jats:title><jats:p>The records of all subjects prospectively presenting to our Department with macroprolactinomas treated with cabergoline over a 2\u2010year period were reviewed. Pituitary function was assessed at diagnosis and, if abnormal, for three consecutive years for the <jats:styled-content style=\"fixed-case\">GH<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> FSH<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">LH<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">ACTH<\/jats:styled-content> axes, and at 3\u00a0years for the <jats:styled-content style=\"fixed-case\">TSH<\/jats:styled-content> axis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twelve patients were included. Severe <jats:styled-content style=\"fixed-case\">GH<\/jats:styled-content> deficiency was found in 83% at diagnosis and did not resolve in any patient at last assessment. Gonadotrophin deficiency was found in 90% at diagnosis and in 50% at last evaluation (showing reversal in 44% of deficient patients, all achieved within 1\u00a0year). <jats:styled-content style=\"fixed-case\">ACTH<\/jats:styled-content> deficiency was found in 17% at diagnosis and it did not reverse in any patient at last assessment. <jats:styled-content style=\"fixed-case\">TSH<\/jats:styled-content> deficiency was found in 36% at diagnosis and in 27% at last assessment (reversal in 25% of deficient patients).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In our study, in a group of patients with macroprolactinoma systematically assessed at intervals, pituitary dysfunction in response to cabergoline was found to be mostly irreversible, except for the gonadotroph axis which showed restoration in a subset of subjects following achievement of normoprolactinaemia. It would appear that the reversibility of pituitary axes may be less common than previously thought.<\/jats:p><\/jats:sec>","DOI":"10.1111\/cen.12124","type":"journal-article","created":{"date-parts":[[2012,12,11]],"date-time":"2012-12-11T17:26:06Z","timestamp":1355246766000},"page":"217-223","source":"Crossref","is-referenced-by-count":28,"title":["Does hypopituitarism recover when macroprolactinomas are treated with cabergoline?"],"prefix":"10.1111","volume":"79","author":[{"given":"Niki","family":"Karavitaki","sequence":"first","affiliation":[{"name":"Department of Endocrinology Oxford Centre for Diabetes, Endocrinology and Metabolism Churchill Hospital Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxandra","family":"Dobrescu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Oxford Centre for Diabetes, Endocrinology and Metabolism Churchill Hospital Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James V.","family":"Byrne","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology John Radcliffe Hospital Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley B.","family":"Grossman","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Oxford Centre for Diabetes, Endocrinology and Metabolism Churchill Hospital Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A. H.","family":"Wass","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Oxford Centre for Diabetes, Endocrinology and Metabolism Churchill Hospital Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,5,6]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2009.03667.x"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780199204854.003.1302"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1025377816769"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.9.3053"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030979"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1692"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2000.01137.x"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-60-4-698"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.1993.02160340043011"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-06-0646"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-101-6-783"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2006.02627.x"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0643"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-13-2-220"},{"key":"e_1_2_5_16_1","first-page":"277","article-title":"Serial imaging in macroprolactinomas: for how long?","volume":"19","author":"Diacono F.","year":"2009","journal-title":"Endocrine Abstracts"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcen.12124","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cen.12124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T15:30:35Z","timestamp":1696347035000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cen.12124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,6]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["10.1111\/cen.12124"],"URL":"https:\/\/doi.org\/10.1111\/cen.12124","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,6]]}}}